Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850979 | 0.81 | CRHR1 (0.50) | CRHR1GABRA2GABRB2 | |
| SCHEMBL6850838 | 0.75 | CRHR1 (0.43) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7979473 | 0.71 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7533738 | 0.65 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL7620645 | 0.63 | CRHR1 (0.93) | CRHR1 | |
| SCHEMBL5492052 | 0.63 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL6850852 | 0.62 | GABRA2 (0.39) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7220186 | 0.61 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL27564981 | 0.59 | GABRA2 (0.48) | CRHR1GABRA2GABRB2 | |
| SCHEMBL7356524 | 0.59 | CRHR1 (0.62) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6514982-B1 | Corticotropin releasing factor is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotropic hormone, beta -endorphin, and other pro-opiomelanocortin-derived peptides from the pituitary | NEUROCRINE BIOSCIENCES, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1129091-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1129091-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | Neurocrine Biosciences, Inc. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027846-A2 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | CRHR1 1/4885GABRA2 147/4885GABRB2 171/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | CRHR1 1/4885GABRA2 147/4885GABRB2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.